Abstract 1146P
Background
Retifanlimab, a programmed death receptor-1 (PD-1)–blocking antibody, was recently approved in the United States for treatment of adult patients (pts) with metastatic or recurrent locally advanced MCC based on results from the open-label, single-arm POD1UM-201 study (NCT03599713). In the primary analysis including 65 chemotherapy-naive pts, responses were observed in 52% (95% CI: 40–65) of pts with 62% of responses exceeding 12 months by landmark analysis (ZYNYZTM prescribing information). Safety was as expected for the PD-(L)1 inhibitor class. We present updated results on the full cohort of 101 pts.
Methods
Eligible pts were ≥18 years of age, had metastatic or recurrent unresectable loco-regional MCC, Eastern Cooperative Oncology Group (ECOG) performance status ≤1, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, and had not received prior MCC systemic treatment. Retifanlimab 500 mg was administered intravenously every 4 weeks (Q4W) for up to 2 years without premedication prophylaxis. The primary endpoint was overall response rate assessed by independent central review per RECIST v1.1. Secondary endpoints included duration of response, disease control rate, progression-free survival, overall survival, safety, and pharmacokinetics.
Results
The study enrolled 101 pts with chemotherapy-naive advanced/metastatic MCC, with the last pt initiating treatment on 24 June 2021. Pt and disease characteristics were representative of the typical MCC epidemiology. The median age was 71 (range, 38–90) years, 68 (67%) pts were male and predominantly white, 74 (73%) had an ECOG of 0, and one pt was HIV positive. A total of 91 (90%) pts had Stage IV disease, 69 (68%) had prior surgery, and 37 (37%) had prior radiotherapy. In evaluable tumour samples, Merkel cell polyomavirus was detectable in 73/96 (76%) and 83/95 (87%) had PD-L1 expression ≥1%. Efficacy and safety results for the full study population will be presented.
Conclusions
Retifanlimab has shown notable clinical activity with an acceptable safety in advanced/metastatic chemotherapy-naive MCC, and is a promising new treatment option for eligible pts.
Clinical trial identification
NCT03599713, EudraCT 2018-001627-39.
Editorial acknowledgement
Envision Pharma Group (Philadelphia, PA), funded by Incyte Corporation (Wilmington, DE).
Legal entity responsible for the study
Incyte Corporation (Wilmington, DE).
Funding
Incyte Corporation, Wilmington, DE.
Disclosure
G. Grignani: Financial Interests, Institutional, Other, Honoraria: Bayer, Eisai, Eli Lilly and Company, Merck, Novartis, Pfizer, PharmaMar; Financial Interests, Institutional, Advisory Role: Bayer, Eisai, Eli Lilly and Company, Novartis, Pfizer, PharmaMar; Financial Interests, Institutional, Research Grant: Bayer, Novartis, PharmaMar. P. Rutkowski: Financial Interests, Institutional, Advisory Board, Honoraria: AstraZeneca Blueprint Medicines, Bristol Meyers Squibb, Merck Serono, MSD, Novartis, Philogen, Pierre Fabre, Sanofi; Financial Interests, Institutional, Other, Institutional support: Pfizer. C. Lebbe: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, MSD, Novartis, Amgen, Roche, Merck Serono, Sanofi, Pierre Fabre; Financial Interests, Personal, Funding: Roche, Bristol Myers Squibb; Non-Financial Interests, Advisory Role: Bristol Myers Squibb, MSD, Novartis, Amgen, Roche, Merck Serono, Sanofi, Pierre Fabre; Other, Honoraria, Speaker's Bureau, Research funding: Roche; Other, Honoraria, Speaker's bureau, Travel, Accommodation, Expenses, Research funding, Board: Bristol Myers Squibb; Other, Honoraria, Speaker's bureau, Travel, Accommodations, Expenses, Board: Novartis, MSD; Other, Honoraria, Speaker's bureau: Amgen; Other, Honoraria, Travel, Accommodations, Expenses, Board: Pierre Fabre; Other, Honoraria: Pfizer; Other, Honoraria: Incyte; Other, Travel, accommodations, Expenses, Board: Sanofi; Other, Board: Avantis Medical Systems, Jazz Pharmaceuticals; Other, Participation on a Data Safety Monitoring Board or Advisory Board: InflaRx. M. Guida: Financial Interests, Institutional, Advisory Role: Bristol Myers Squibb, MSD, Novartis, Pierre Fabre. C. Gaudy Marqueste: Financial Interests, Institutional, Advisory Board, Honoraria: Bristol Myers Squibb, MSD, Pierre Fabre; Financial Interests, Institutional, Other, Participated in clinical trials and Travel grants: Bristol Myers Squibb, MSD, Pierre Fabre; Financial Interests, Institutional, Other, Participated in clinical trials: GSK, Huyabioscience, Incyte, Merck Serono, Novartis, Regeneron, Replimune, Kartos. F.G.M. De Braud: Financial Interests, Institutional, Advisory Role: Roche, EMD Serono, NMS Nerviano Medical Science, Sanofi, MSD, Incyte, Bristol Myers Squibb, Menarini, AstraZeneca, Pierre Fabre, Mattiolo 1885 , MCCann Health, Taiho; Financial Interests, Institutional, Speaker’s Bureau: Bristol Myers Squibb, Healthcare Research & Pharmacoepidemiology, Merck, MSD, Pfizer, Servier, Sanofi, Roche, Amgen, Incyte, Dephaforum, Seagen, Nadirex, Ambrosetti, Itanet; Financial Interests, Funding, Research: Novartis, Hoffmann LaRoche Ltd., Bristol Myers Squibb, Ignyta Operating INC, Kymab, Pfizer, Tesaro, MSD, MedImmune LCC, Exelixis Inc., Loxo Oncology Incorporated, Daiichi Sankyo Dev. Limited, Basilea Pharmaceutica International AG, Janssen Cilag International NV, Merck KGaA, IQVIA. F. Spagnolo: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Merck, MSD, Novartis, Pierre Fabre, Philogen, Sanofi, Sun Pharma. M. Burgess: Financial Interests, Institutional, Funding, Research: Merck; Financial Interests, Institutional, Advisory Board: EMD Serono, Immune Design, SpringWorks Therapeutics. H. Montaudie: Financial Interests, Institutional, Other, Honoraria: Bristol Myers Squibb, Merck Serono, MSD, Novartis, Pierre Fabre; Financial Interests, Institutional, Other, Institutional support: Bristol Myers Squibb, Leo Pharma; Financial Interests, Institutional, Other, Participated in clinical trials: Bristol Myers Squibb, Checkpoint Therapeutics, Huyabioscience, Incyte, Merck Serono, MSD, Nektar Pharmaceuticals, Novartis, Pierre Fabre, Regeneron, Replimune; Financial Interests, Institutional, Other, Travel grant: Bristol Myers Squibb, Pierre Fabre, Novartis. R. Depenni: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, MSD, Novartis, Pierre Fabre, Sanofi. F. Spada: Financial Interests, Institutional, Other, Honoraria for lectures and/or advisory boards and/or manuscript writing: Advanced Accelerator Application, Ipsen, Merck/MSD, Novartis, Pfizer; Financial Interests, Institutional, Invited Speaker, Institutional support: GETNE, Hutchmed, Incyte Corporation. J. Pulini, M. Cornfeld, C. Tian: Financial Interests, Institutional, Full or part-time Employment: Incyte; Financial Interests, Institutional, Stocks/Shares: Incyte. S. Bhatia: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Castle Biosciences, EMD Serono, Exicure, Genentech, Incyte, Sanofi-Genzyme; Financial Interests, Institutional, Research Grant: 4SC, Amphivena Therapeutics, Bristol Myers Squibb, Checkmate, EMD Serono, Immune Design, Incyte Biosciences, Merck, NantKwest, Nektar, Novartis, OncoSec, Regeneron, Xencor; Financial Interests, Institutional, Stocks/Shares: Moderna.
Resources from the same session
1129P - Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
Presenter: Marlana Orloff
Session: Poster session 13
1130P - Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Presenter: Leah Mailly-Giacchetti
Session: Poster session 13
1131P - Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting
Presenter: Mauricio Fernando Ribeiro
Session: Poster session 13
1132P - Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy
Presenter: Aparna Nallagangula
Session: Poster session 13
1133P - SF3B1 mutation predicts improved overall survival in metastatic uveal melanoma patients: Molecular and clinical correlates
Presenter: Luis del Carpio Huerta
Session: Poster session 13
1134P - Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Presenter: Isabella Glitza
Session: Poster session 13
1135P - Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Presenter: Raymond Huang
Session: Poster session 13
1136P - Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases
Presenter: Iris Dirven
Session: Poster session 13
1138P - Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity
Presenter: Lukas Flatz
Session: Poster session 13